Life Sciences
Fabrx's pharmaceutical 3D printing platform is used for research and small batch manufacture of personalized medicine and medical devices.
The round follows a $200 million seed raise earlier this year.
The aim is to utilize Hippocratic AI's agents to keep patients informed, supportive and connected.
The alliance will center on the discovery, development and commercialization of radioligand therapies for imaging and treatment of solid tumors.
The aim of Agent Studio is to free up teams, accelerate trials, reduce costs and bring medicines to patients faster.
The acquisition joins SeqOne's platform for sequencing analysis with Congenica's clinical decision support technology.
The alliance aims to accelerate clinical trial recruitment by using large language models to hasten and scale patient identification.
The acquisition will allow Tempus to expand its technical team and create a stronger presence in digital pathology.
Ozempic and Wegovy pens will be available via GoodRx for $499 per month.
International Space Station-sponsored investigations target stem cells and microbial infections in space.